Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (32 quarters reported)
$104M in Q4 2018 → $1.05B now. Hover for any quarter.
As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| SR Scholar Rock Hldg Corp | 31.7% | Unchanged | 6,897,652 | $333M |
| Mineralys Therapeutics Inc | 14.0% | Unchanged | 5,871,018 | $148M |
| Septerna Inc | 11.4% | Trimmed 2.6% | 3,066,453 | $120M |
| Alamar Biosciences Inc | 8.0% | Unchanged | 2,480,310 | $84.5M |
| Spyglass Pharma Inc | 5.2% | Unchanged | 2,109,953 | $54.9M |
| Alumis Inc | 5.1% | Added 14% | 7,235,809 | $53.5M |
| Neurogene Inc | 4.9% | Added 8.7% | 1,867,127 | $51.9M |
| Kalaris Therapeutics Inc | 3.5% | Unchanged | 12,881,175 | $37.2M |
| IS Inventiva Sa | 2.2% | Unchanged | 6,314,805 | $23.3M |
| PM Parabilis Medicines Inc | 1.7% | Unchanged | 556,044 | $18M |
| Sutro Biopharma Inc | 1.6% | Unchanged | 1,062,872 | $17.1M |
| Pmv Pharmaceuticals Inc | 1.1% | New | 7,240,000 | $12.1M |
| Obsidian Therapeutics Inc | 1.1% | New | 837,173 | $11.5M |
| Aquestive Therapeutics Inc | 1.1% | Trimmed 2.6% | 2,434,367 | $11.3M |
| Vtv Therapeutics Inc | 1.0% | Added 19% | 354,730 | $10.9M |
| Jade Biosciences Inc | 1.0% | Unchanged | 736,237 | $10.3M |
| Nkarta Inc | 0.9% | Unchanged | 3,507,666 | $9.19M |
| RT Rani Therapeutics Hldgs Inc | 0.8% | Unchanged | 10,369,159 | $8.2M |
| Artiva Biotherapeutics Inc | 0.6% | Unchanged | 954,861 | $6.8M |
| Agomab Therapeutics Nv | 0.6% | Trimmed 0.9% | 594,749 | $6.6M |
| EP Eloxx Pharmaceuticals Inc | 0.6% | Unchanged | 400,000 | $6.12M |
| AS Abivax Sa | 0.5% | Unchanged | 55,095 | $5.46M |
| Coherus Oncology Inc | 0.4% | Trimmed 1.3% | 3,383,565 | $4.09M |
| X4 Pharmaceuticals Inc | 0.4% | Trimmed 3.4% | 1,347,723 | $3.91M |
| Upstream Bio Inc | 0.2% | Trimmed 15% | 300,361 | $1.58M |
| TA Tcgx Acquisition Corp | 0.1% | New | 100,000 | $1.25M |
| Gossamer Bio Inc | 0.1% | New | 87,956 | $1.04M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2026 · filed November 16, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Pmv Pharmaceuticals Inc | New | +7,240,000 | +$12.1M | 1.1% |
| Obsidian Therapeutics Inc | New | +837,173 | +$11.5M | 1.1% |
| Alumis Inc | Added | +890,590 | +$6.58M | 5.1% |
| Neurogene Inc | Added | +150,000 | +$4.17M | 4.9% |
| Septerna Inc | Trimmed | −82,675 | −$3.24M | 11.4% |
| Vtv Therapeutics Inc | Added | +56,234 | +$1.73M | 1.0% |
| TA Tcgx Acquisition Corp | New | +100,000 | +$1.25M | 0.1% |
| Gossamer Bio Inc | Exited | −7,222,559 | −$1.19M | — |
| Gossamer Bio Inc | New | +87,956 | +$1.04M | 0.1% |
| Aquestive Therapeutics Inc | Trimmed | −65,633 | −$304K | 1.1% |
Showing the 10 largest of 14 changes.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Alamar Biosciences Inc | New | +2,480,310 | +$67.2M | 5.5% |
| PM Parabilis Medicines Inc | New | +556,044 | +$15.2M | 1.3% |
| Artiva Biotherapeutics Inc | New | +954,861 | +$9.26M | 0.8% |
| Arcellx Inc | Exited | −60,873 | −$6.99M | — |
| EP Eloxx Pharmaceuticals Inc | New | +400,000 | +$5.55M | 0.5% |
| Jade Biosciences Inc | Trimmed | −232,561 | −$5.17M | 1.3% |
| PT Palvella Therapeutics Inc Ne | Exited | −38,432 | −$4.79M | — |
| IS Inventiva Sa | Added | +1,120,000 | +$4.23M | 2.0% |
| Upstream Bio Inc | Trimmed | −382,330 | −$2.65M | 0.2% |
| X4 Pharmaceuticals Inc | Trimmed | −436,979 | −$2.04M | 0.5% |
Showing the 10 largest of 13 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Spyglass Pharma Inc | New | +2,109,953 | +$54.7M | 5.3% |
| Sutro Biopharma Inc | Added | +858,369 | +$21.4M | 2.6% |
| Alumis Inc | Added | +588,235 | +$13M | 13.6% |
| PT Palvella Therapeutics Inc Ne | Trimmed | −66,385 | −$8.27M | 0.5% |
| Agomab Therapeutics Nv | New | +600,000 | +$6.29M | 0.6% |
| Coherus Oncology Inc | New | +3,428,571 | +$5.79M | 0.6% |
| AS Abivax Sa | Trimmed | −18,861 | −$2.1M | 0.6% |
| Contineum Therapeutics Inc | Exited | −72,245 | −$826K | — |
| X4 Pharmaceuticals Inc | Trimmed | −127,434 | −$526K | 0.7% |
| Nuvation Bio Inc | Exited | −124,119 | −$41K | — |
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SR Scholar Rock Hldg Corp | Added | +1,284,756 | +$56.6M | 31.3% |
| IS Inventiva Sa | New | +5,194,805 | +$24.2M | 2.5% |
| Lenz Therapeutics Inc | Exited | −343,012 | −$16M | — |
| Mineralys Therapeutics Inc | Trimmed | −392,133 | −$14.2M | 22.0% |
| Kalaris Therapeutics Inc | Added | +1,500,000 | +$12.7M | 11.3% |
| RT Rani Therapeutics Hldgs Inc | New | +8,500,000 | +$11.5M | 1.2% |
| PT Palvella Therapeutics Inc Ne | Trimmed | −104,817 | −$11M | 1.1% |
| AP Avadel Pharmaceuticals PLC | Exited | −675,504 | −$10.3M | — |
| Alumis Inc | Added | +955,614 | +$9.33M | 5.8% |
| X4 Pharmaceuticals Inc | New | +1,960,000 | +$7.84M | 0.8% |
Showing the 10 largest of 27 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Mineralys Therapeutics Inc | Added | +588,235 | +$22.3M | 31.0% |
| Cargo Therapeutics Inc | Exited | −4,415,689 | −$18.2M | — |
| Aquestive Therapeutics Inc | New | +2,500,000 | +$14M | 1.8% |
| Upstream Bio Inc | Trimmed | −481,077 | −$9.05M | 2.4% |
| PT Palvella Therapeutics Inc Ne | Trimmed | −130,109 | −$8.16M | 1.7% |
| AS Abivax Sa | New | +75,442 | +$6.41M | 0.8% |
| Vtv Therapeutics Inc | Added | +167,677 | +$3.92M | 1.1% |
| Aura Biosciences Inc | Trimmed | −415,151 | −$2.57M | 0.5% |
| Rhythm Pharmaceuticals Inc | Trimmed | −20,191 | −$2.04M | 0.4% |
| Zymeworks Inc | Trimmed | −102,399 | −$1.75M | 0.5% |
Showing the 10 largest of 17 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| PT Palvella Therapeutics Inc Ne | Trimmed | −339,743 | −$7.66M | 1.6% |
| Upstream Bio Inc | Trimmed | −623,915 | −$6.85M | 3.2% |
| Aura Biosciences Inc | New | +1,000,000 | +$6.26M | 1.3% |
| Acelyrin Inc | Exited | −2,523,022 | −$6.23M | — |
| Rhythm Pharmaceuticals Inc | Trimmed | −87,642 | −$5.54M | 0.7% |
| Lenz Therapeutics Inc | Trimmed | −183,378 | −$5.37M | 2.1% |
| Jade Biosciences Inc | New | +531,163 | +$5.31M | 1.1% |
| Alumis Inc | Added | +1,534,872 | +$4.6M | 2.9% |
| Zymeworks Inc | Trimmed | −356,367 | −$4.47M | 0.8% |
| Onkure Therapeutics Inc | Exited | −824,155 | −$3.54M | — |
Showing the 10 largest of 23 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Kalaris Therapeutics Inc | New | +11,448,081 | +$91.9M | 16.4% |
| Jasper Therapeutics Inc | Exited | −584,642 | −$12.5M | — |
| Lenz Therapeutics Inc | Trimmed | −460,591 | −$11.8M | 2.4% |
| Mineralys Therapeutics Inc | Added | +600,000 | +$9.53M | 16.1% |
| Arcellx Inc | Trimmed | −118,365 | −$7.76M | 1.6% |
| Aclaris Therapeutics Inc | Exited | −2,385,060 | −$5.91M | — |
| Climb Bio Inc | Exited | −2,609,114 | −$4.7M | — |
| Verona Pharma PLC | Exited | −97,625 | −$4.53M | — |
| Zymeworks Inc | Trimmed | −333,333 | −$3.97M | 1.4% |
| Surrozen Inc | New | +241,400 | +$2.81M | 0.5% |
Showing the 10 largest of 20 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Septerna Inc | New | +2,768,520 | +$63.4M | 8.7% |
| SR Scholar Rock Hldg Corp | Trimmed | −1,175,713 | −$50.8M | 33.3% |
| Upstream Bio Inc | New | +2,217,146 | +$36.4M | 5.0% |
| Neurogene Inc | Added | +449,337 | +$10.3M | 5.4% |
| PT Palvella Therapeutics Inc Ne | New | +679,486 | +$8.15M | 1.1% |
| Arcellx Inc | Trimmed | −100,000 | −$7.67M | 2.7% |
| Onkure Therapeutics Inc | New | +824,155 | +$7.09M | 1.0% |
| Lenz Therapeutics Inc | Trimmed | −221,492 | −$6.39M | 3.9% |
| Verona Pharma PLC | Trimmed | −97,600 | −$4.53M | 0.6% |
| Aclaris Therapeutics Inc | Added | +1,688,889 | +$4.19M | 0.8% |
Showing the 10 largest of 19 changes.
Loading...